Biotechnology Stock in News; Novavax Inc. – Beacon Equity Research
By Dr. Matthew Watson
 SunHerald.com | Biotechnology Stock in News; Novavax Inc. Beacon Equity Research Novavax Inc. (NASDAQ: NVAX) announced that it has been awarded a government contract for developing flu vaccines. The contract has been awarded to the company in collaboration with VaxInnate Inc. The contract is likely to be worth $215 million. ... Biotechnology Stock on Watch; Novavax Inc.Tech24 Government Backs Futuristic Flu ShotsForbes (blog) N.J. company gets contract for new flu vaccineNewsworks.org (blog) |
Uncategorized
Comments Off on Biotechnology Stock in News; Novavax Inc. – Beacon Equity Research |
March 6th, 2011
This author published 5912 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research